Astigmatism, Cataracts, Far Sightedness
Conditions
Brief summary
Observational post-marketing study with prospective follow-up of CE marked medical devices aimed at the treatment of hyperopia and astigmatism in patients with cataract. The objective is to evaluate the clinical results of the implantation of the monofocal aspheric bitoric intraocular lens (IOL) with AT-TORBI 709 plate haptics in cataract surgery of hyperopic eyes with astigmatism.
Detailed description
All patients participating in the study will have the intraocular lens (IOL) AT TORBI 709 implanted from Carl Zeiss Meditec AG, Jena, Germany, with CE marking. All patients will be treated according to standard clinical practice. A preoperative and postoperative evaluation will be carried out one month, six and twelve months after the intervention where the following tests will be performed: refraction, corneal topography, measurement of visual acuity with and without correction, slit lamp examination, eye biometry using the IOLMaster 700 Carl Zeiss Meditec AG, Jena, Germany, CE marked optical non-contact biometer, contrast sensitivity with the CC-100 screen (Topcon Europe, The Netherlands), and the Catquest-9SF (European Registry of Quality Outcomes for Cataract and Refractive Surgery, founded by the European Society of Cataract and Refractive Surgeons). The sponsor has received an unrestricted research grant by Zeiss.
Interventions
DEVICEImplant of the AT-TORBI 709 lens
Implant of the AT-TORBI 709 lens
Sponsors
Carl Zeiss Meditec AG
OFTALVIST (Oftalmología Vistahermosa S.L)
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients of 50 years of age or older to undergo cataract surgery with phacoemulsification 2. Patient who signs the informed consent. 3. Regular corneal astigmatism between 1.0D and 4.0D. 4. IOL power between 21D and 26D 5. Target-target distance measured with the IOLMaster 700 biometer (Carl Zeiss Meditec AG) greater than 11.6 mm. 6. Patients with hyperopia between 1.0D and 4.0D.
Exclusion criteria
1. Patients who do not provide informed consent 2. Patients who do not understand the study procedure 3. Previous corneal surgery. 4. Irregular cornea (eg keratoconus) 5. myopic patients 6. Eye abnormalities or pathologies that could reduce the visual function or stability of the IOL (eg severe amblyopia or macular degeneration)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of the refractive error | 12 months | Measurement of the refractive error (equivalent spherical error, the refractive cylinder and the astigmatism vectors (J0 and J45) ) |
| Measurement of the rotational stability | 12 months | Measurement of the rotational stability |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure of ocular biometry | 12 months | Measure of ocular biometry |
| Measure of contrast sensitivity | 12 months | Measure of contrast sensitivity |
| Measure of visual acuity | 12 months | Measurement of visual acuity |
| Slit lamp examination | 12 months | Slit lamp examination |
| Satisfaction questionaire | 12 months | For several questions percentage of respondants answering each of five possible provided answers ranging progressively from strong disatisfaction to strong satisfaction (1-4) as well as an answer for those patients who cannot decide (5) |
| Measure of corneal topography | 12 months | Measure of corneal topography |
Countries
Spain
Outcome results
None listed